Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs, has appointed Mohammad Ahmadian as Vice President of Chemistry and Pharmaceutical Development.
In his role, Dr. Ahmadian will assist in managing research and development of the company’s drug candidates, including RGLS8429, which is being developed for patients with autosomal dominant polycystic kidney disease (ADPKD), and will add significant expertise to Regulus’ existing scientific talent.
“We are excited to welcome Moh to the Regulus team,” said Denis Drygin, Chief Scientific Officer of Regulus. “Moh brings over 20 years of drug discovery and development experience to the company and we believe his background working specifically with oligonucleotides makes him uniquely qualified for the position. We look forward to drawing on his expertise as we continue to make strides in developing RGLS8429, as well as our research programmes.”
Prior to joining Regulus, Dr. Ahmadian was Vice President & Resident Director of Kinovate Life Sciences, where in addition to serving as the technical lead, he was responsible for operations, including overseeing production, quality control, quality assurance and the supply chain.
Prior to Kinovate, Dr. Ahmadian was employed with Nitto Denko Technical Corporation where he managed various projects concerning design, manufacturing and process development of therapeutic oligonucleotides. Previously, he worked for various life sciences companies as a research chemist and manager of RNA chemistry projects.
Dr. Ahmadian holds a Ph.D. in medicinal chemistry from Purdue University and an M.Sc. in organic chemistry from Ball State University.
Image credit: Regulus Therapeutics